 AC Immune SA NASDAQ: ACIU and its partner Janssen Pharmaceuticals Inc have expanded the ongoing Phase 1b2a trial evaluating anti-phosphorylated-Tau pTau vaccine candidate ACI-35.030 for the treatment of Alzheimers disease AD. The trial expansion specifically includes vaccination of additional AD patients at the second-highest dose. 